Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Net: 2020-2023

Historic Receivables - Net for SAB Biotherapeutics (SABS) over the last 1 years, with Jun 2023 value amounting to $364,117.

  • SAB Biotherapeutics' Receivables - Net fell 96.21% to $364,117 in Q2 2023 from the same period last year, while for Jun 2023 it was $364,117, marking a year-over-year decrease of 96.21%. This contributed to the annual value of $5.6 million for FY2022, which is 30.64% down from last year.
  • According to the latest figures from Q2 2023, SAB Biotherapeutics' Receivables - Net is $364,117, which was down 52.29% from $763,123 recorded in Q1 2023.
  • SAB Biotherapeutics' 5-year Receivables - Net high stood at $20.6 million for Q4 2020, and its period low was $364,117 during Q2 2023.
  • For the 3-year period, SAB Biotherapeutics' Receivables - Net averaged around $7.0 million, with its median value being $8.0 million (2021).
  • Data for SAB Biotherapeutics' Receivables - Net shows a maximum YoY tumbled of 96.21% (in 2023) over the last 5 years.
  • SAB Biotherapeutics' Receivables - Net (Quarterly) stood at $20.6 million in 2020, then slumped by 61.06% to $8.0 million in 2021, then slumped by 30.64% to $5.6 million in 2022, then plummeted by 96.21% to $364,117 in 2023.
  • Its last three reported values are $364,117 in Q2 2023, $763,123 for Q1 2023, and $5.6 million during Q4 2022.